帕罗西汀治疗帕金森病伴发抑郁障碍临床疗效与安全性分析

被引：15

作者：

苗海锋

马荣

吴志强

石铸

李庆军

刘玉华

陈杭军

机构：

[1] 广东东莞市人民医院综合一科

来源：

中国实用神经疾病杂志 | 2014年 / 04期

关键词：

帕金森病; 左旋多巴; 帕罗西汀; 抑郁障碍;

D O I：

暂无

中图分类号：

R742.5 [震颤麻痹综合征];

学科分类号：

100204 [神经病学];

摘要：

目的探讨抗抑郁药帕罗西汀治疗帕金森病伴抑郁患者的疗效和不良反应。方法将50例帕金森病伴抑郁患者按随机数字表法分为治疗组和对照组,每组25例。2组均给予帕金森病的常规治疗,治疗组同时给予帕罗西汀片20mg,每日晨起顿服,对照组不使用任何抗抑郁药物,均持续治疗8周。在治疗前及治疗1、4、8周后分别进行统一帕金森病评定量表(The unified Parkinson‘s disease rating scale,UPDRS)评分、汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)评分,统计左旋多巴每日服用总量,使用不良反应量表(Treatment Emergent SymptomScale,TESS)评价其安全性。结果治疗8周后UPDRS评分2组比较差异有统计学意义(t=2.0678,P=0.0441),治疗4、8周后HAMD评分2组比较差异均有统计学意义(4周:t=2.1746,P=0.0346;8周:t=2.3080,P=0.0254),治疗8周后每日服用左旋多巴总量2组比较差异有统计学意义(t=2.0606,P=0.0448),治疗前和治疗8周后TESS评分2组比较差异无统计学意义(t=0.1101,P=0.9128)。结论帕罗西汀治疗帕金森病伴抑郁患者疗效确切,可减少左旋多巴用量,安全性良好。

引用

页码：9 / 12

页数：4

共 12 条

[1]

恩他卡朋添加治疗有剂末现象帕金森病的初步研究 [J].

苗海锋 ;

肖卫民 .

海南医学, 2008, (10) :7-9

[2]

帕金森病及帕金森综合征的诊断标准和鉴别诊断[J] 王新德; 中华精神科杂志 1985,

[3]

Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life[J] Nico J. Weerkamp;Gerrit Tissingh;Petra J.E. Poels;Systse U. Zuidema;Marten Munneke;Raymond T.C.M. Koopmans;Bastiaan R. Bloem J Am Geriatr Soc 2013,

[4]

Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms[J] Celine Perier;Andreas Bender;Elena García-Arumí;Ma Jesus Melià;Jordi Bové;Christoph Laub;Thomas Klopstock;Matthias Elstner;Ross B. Mounsey;Peter Teismann;Tomas Prolla;Antoni L. Andreu;Miquel Vila Brain 2013,

[5]

Major life events and development of major depression in P arkinson's disease patients[J] N. H. Rod;Y. Bordelon;A. Thompson;E. Marcotte;B. Ritz Eur J Neurol 2012,

[6]

Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions[J] R. Mandrioli;L. Mercolini;M. A. Saracino;M. A. Raggi Current Medicinal Chemistry 2012,

[7]

A randomized; double-blind; placebo-controlled trial of antidepressants in Parkinson disease[J] I.H. Richard;M.P. McDermott;R. Kurlan;J.M. Lyness;P.G. Como;N. Pearson;S.A. Factor;J. Juncos;C. Serrano Ramos;M. Brodsky;C. Manning;L. Marsh;L. Shulman;H.H. Fernandez;K.J. Black;M. Panisset;C.W. Christine;W. Jiang;C. Singer;S. Horn;R. Pfeiffer;D. Rottenberg;J. Slevin;L. Elmer;D. Press;H.C. Hyson;W. McDonald;Irene Richard;William McDonald;Michael McDermott;Peter G. Como;Roger Kurlan;Jeffrey M. Lyness;N

[8]

Depression in Parkinson?s Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management[J] Roseanne DeFronzo Dobkin;Matthew Menza;Karina L. Bienfait;Michael Gara;Humberto Marin;Margery H. Mark;Allison Dicke;Jill Friedman American Journal of Geriatric Psychiatry 2011,

[9]

Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder[J] Jan C. Beucke;Idun Uhl;Michail Plotkin;Christine Winter;Hans-Jörg Assion;Tanja Endrass;Holger Amthauer;Andreas Kupsch;Georg Juckel World Journal of Biological Psychiatry 2010,

[10]

Anxiety disorders in Parkinson's disease: Prevalence and risk factors[J] Nadeeka N.W.Dissanayaka;AnnaSellbach;SallyMatheson;John D.O'Sullivan;Peter A.Silburn;Gerard J.Byrne;RodneyMarsh;George D.Mellick Mov. Disord. 2010,

← 1 2 →